Sun Pharma psoriatic arthritis drug trials meet primary endpoint

Sun Pharmaceutical Industries reported its two Phase 3 clinical studies, INSPIRE-1 and INSPIRE-2, evaluating tildrakizumab 100 mg for active psoriatic arthritis, successfully met their primary endpoint.

Both studies showed statistically significant improvements in ACR20 response rates at Week 24 compared to placebo. The positive results support a potential regulatory submission in the US.

Safety data was consistent with the drug's known safety profile, with no new safety signals identified.